Two Brain Cell Types Linked to Depression: What a Landmark Study Actually Shows — and What It Doesn't

A study published in Nature Genetics has identified two specific brain cell types that behave differently in people with major depressive disorder — deep-layer excitatory neurons and a subtype of microglia [1]. The finding, from researchers at McGill University and the Douglas Research Centre, is the first to map both gene activity and the regulatory mechanisms controlling DNA in individual brain cells of people with depression [2]. But the distance between identifying a cellular signature and developing a treatment remains vast, and the history of depression neuroscience is littered with breakthroughs that failed to deliver cures.

The Study: What Was Done

The research team, led by senior author Dr. Gustavo Turecki and first author Anjali Chawla, used a technique called single-nucleus ATAC-seq — a method that profiles chromatin accessibility, meaning how open or closed regions of DNA are in individual cells, which determines which genes can be switched on or off [1]. They combined this with single-nucleus RNA sequencing data to build a detailed picture of gene regulation at the single-cell level [2].

The scientists examined postmortem brain tissue from 100 individuals: 59 diagnosed with major depressive disorder (MDD) and 41 neurotypical controls [2]. The tissue came from the Douglas-Bell Canada Brain Bank, one of the few repositories in the world that collects donated brain tissue from people with psychiatric conditions [3]. All samples were taken from the dorsolateral prefrontal cortex, a brain region involved in executive function, decision-making, and emotional regulation [4]. In total, the team analyzed over 200,000 individual cells [4].

The Findings: Two Cell Types, Two Disrupted Systems

The analysis revealed depression-associated changes concentrated in two cell populations.

The first was a group of deep-layer excitatory neurons — cells that send activating signals in the brain and are involved in mood regulation and stress response. In people with depression, these neurons showed altered accessibility of transcription factor motifs, particularly for NR4A2, an activity-dependent transcription factor that responds to stress [1]. These same neurons were enriched for genetic variants previously associated with MDD through genome-wide association studies, and the disrupted transcription factor binding sites were linked to genes that affect synaptic communication — the process by which neurons signal to each other [4].

The second was a cluster of gray matter microglia, the brain's resident immune cells. In individuals with MDD, these microglia showed decreased chromatin accessibility at binding sites for transcription factors known to regulate immune homeostasis [4]. This finding connects to a growing body of evidence implicating neuroinflammation — chronic, low-grade immune activation in the brain — as a contributor to depression [5].

"This is the first time we've been able to identify what specific brain cell types are affected in depression by mapping gene activity together with mechanisms that regulate the DNA code," Dr. Turecki said [3].

The Scale of the Problem

Depression affects an estimated 280 million people worldwide, according to the World Health Organization — roughly 3.8% of the global population and about 5% of all adults [6]. The burden is not evenly distributed. South-East Asia carries the largest regional share at an estimated 83.4 million cases, followed by the Western Pacific (64.3 million) and the Americas (48.2 million) [6].

Source: WHO/IHME Global Health Data

Data as of Mar 31, 2023CSV

Approximately one-third of patients with MDD do not respond adequately to standard antidepressant treatment, a condition classified as treatment-resistant depression (TRD) [7]. The disorder also manifests in distinct subtypes — postpartum depression, bipolar depression, seasonal affective disorder, and others — each with potentially different underlying biology [6]. The McGill study examined only major depressive disorder as broadly defined; it did not stratify results by subtype, treatment history, or resistance status [1]. Whether the cellular signatures identified hold across all forms of depression, or apply only to a subset, remains unknown.

How This Fits With Existing Theories

Depression neuroscience has been shaped by several competing frameworks, none of which has proven sufficient on its own.

The monoamine hypothesis, dominant since the 1960s, holds that depression results from deficiencies in neurotransmitters like serotonin, norepinephrine, and dopamine. It remains the basis for most antidepressants, including SSRIs. But only about one-third of patients improve substantially with SSRIs, and a 2022 umbrella review in Molecular Psychiatry found no consistent evidence that serotonin levels or activity are lower in people with depression [8][5].

The neuroinflammation model posits that overactive immune signaling in the brain contributes to depressive symptoms. Elevated levels of proinflammatory cytokines have been found in many patients with MDD, and microglia — the same cell type flagged in the McGill study — play a central role in this process [5]. The McGill finding reinforces this model by showing specific epigenetic changes in microglia that may impair their ability to maintain immune balance [4].

The neuroplasticity/neurotrophic hypothesis focuses on brain-derived neurotrophic factor (BDNF) and the brain's ability to form new connections. Ketamine, which targets NMDA receptors and promotes BDNF signaling, was first shown to produce rapid antidepressant effects in the early 2000s [9]. Its derivative esketamine received FDA approval in 2019 — roughly two decades after the initial discovery — and remains limited to treatment-resistant cases, requires in-clinic administration, and carries risks of dissociation and abuse [9].

The McGill researchers have not claimed to supersede these frameworks. Their findings are additive: the excitatory neuron changes connect to synaptic and stress-response pathways, while the microglia changes connect to the neuroinflammation model. As a 2025 review in Discover Mental Health noted, "The monoamine, plasticity and inflammation theories of depression are mutually inclusive and influence one another as smaller parts of a larger puzzle" [5].

The Long Road From Cell Type to Drug

The identification of specific cell types and transcription factors offers what researchers call a "druggable target" — a molecular mechanism that could, in theory, be addressed with a therapeutic compound. But the history of neuroscience drug development counsels caution.

Source: Tufts CSDD / PMC

Data as of Jan 1, 2023CSV

The average timeline from preclinical research to FDA approval for a central nervous system drug is approximately 14 years, with Phase II trials (testing efficacy) alone averaging 3.6 years [10]. The median cost of bringing a new drug to market was estimated at $985 million in a 2020 study, with averages reaching $1.3 billion [11]. And only about 12% of drugs entering clinical trials ultimately receive FDA approval — a rate that is even lower for CNS compounds, where the complexity of the brain and the blood-brain barrier present additional obstacles [10][11].

The BDNF/ketamine pathway illustrates the timeline problem. Initial observations of ketamine's rapid antidepressant effects were published in 2000. Esketamine (Spravato) was approved by the FDA in 2019 — 19 years later — and the drug remains narrowly indicated, with significant clinical limitations [9]. Even if the McGill findings lead directly to a drug development program, a similar multi-decade timeline would be a reasonable expectation.

Scientific Critiques and Limitations

Several methodological factors warrant scrutiny.

Postmortem tissue. The study relied entirely on brain tissue from deceased individuals. While this is standard in human neuroscience — live brain biopsies are ethically and practically impossible for research purposes — postmortem tissue captures a single snapshot in time. It cannot show whether the observed cellular changes caused depression, resulted from it, or arose from confounding factors like medication use, substance use, or the manner of death [12].

Sample demographics. The study included 100 individuals, a modest sample by the standards of genomic research. The McGill press materials did not provide detailed demographic breakdowns by race, ethnicity, or socioeconomic status [3]. Previous single-cell studies of depression have found sex-specific differences: one 2023 study in Nature Communications found that microglia and parvalbumin interneurons contributed the most differentially expressed genes in females, while deep-layer excitatory neurons, astrocytes, and oligodendrocyte precursors were the major contributors in males [13]. Whether the McGill study adequately powered for sex differences is unclear from the published summary.

The heterogeneity problem. Depression is not a single disease. It encompasses a broad spectrum of symptoms, courses, and probable causes. A 2020 study in Biological Psychiatry identified multiple neurobiologically distinct subtypes using neuroimaging and genetics [14]. Single-cell transcriptomics studies have found that over 60% of the 26 distinct cellular clusters they identified showed transcriptional differences in MDD — suggesting that the condition involves many cell types, not just two [12]. The identification of two particularly affected cell types does not mean other cell types are uninvolved; it means these two showed the strongest signal in this particular brain region with this particular method.

Single brain region. The study examined only the dorsolateral prefrontal cortex. Depression involves a distributed network of brain regions, including the amygdala, hippocampus, anterior cingulate cortex, and nucleus accumbens [12]. Whether the same cellular changes appear in other regions is unknown. Earlier studies have profiled up to six corticolimbic structures and found region-specific patterns [12].

No independent replication. As of this writing, the findings have not been replicated by an independent laboratory. The study represents a single group's analysis of one brain bank's tissue collection [1][3].

Funding and Conflicts of Interest

The study was funded by the Canadian Institutes of Health Research, the Brain Canada Foundation, the Fonds de recherche du Québec – Santé, and the Healthy Brains, Healthy Lives initiative at McGill University [3]. These are all public or nonprofit funding sources. Dr. Turecki holds a Canada Research Chair in Major Depressive Disorder and Suicide [3]. In a separate project involving the AI startup Aifred Health, which develops tools for personalizing psychiatric treatment, conflicts of interest were managed by routing publications through Dr. Turecki, who was noted to have no financial interest in that company [15]. The Nature Genetics paper's specific competing interests disclosures were not accessible for independent review at the time of reporting.

The Research Landscape

The McGill study arrives during a period of rapid growth in single-cell neuroscience research. Academic publications on depression neurobiology and single-cell techniques have grown from roughly 1,247 papers in 2011 to a peak of 5,639 in 2023, reflecting the maturation of single-cell sequencing technologies and their application to psychiatric conditions [16].

Source: OpenAlex

Data as of Jan 1, 2026CSV

This volume of research has produced real progress. The FDA approved brexanolone (2019) and zuranolone (2023) for postpartum depression, both targeting GABA receptors. Esketamine was approved for treatment-resistant depression in 2019, and dextromethorphan/bupropion for MDD in 2022 [7]. Each of these approvals followed decades of basic research into the mechanisms they target.

What This Means

The McGill study is a genuine technical achievement. Profiling chromatin accessibility at the single-cell level in postmortem brain tissue, and linking those profiles to known genetic risk variants, represents a meaningful advance in understanding the biology of depression. The convergence of their excitatory neuron findings with genetic association data strengthens the case that these cells play a role in the disorder.

But the study does not identify "the brain cells behind depression" in the way some headlines have suggested. It identifies two cell types with altered gene regulation in one brain region of people who had depression. That is a specific, valuable finding — not a complete explanation.

For the 280 million people living with depression worldwide, the practical implications remain distant. The study opens a research direction, not a treatment pipeline. The question now is whether other laboratories can replicate the findings, extend them to additional brain regions and depression subtypes, and determine whether targeting NR4A2 or microglial transcription factors produces therapeutic effects in animal models — the first of many steps before any clinical application becomes plausible.